Role of transporters in pancreatic cancer drug resistance

Role of transporters in pancreatic cancer drug resistance

Show other versions (3)

Pancreatic cancer (PC) is known to be highly resistant to chemotherapy. Transporters, which regulate the influx and efflux of substrates across the plasma membrane, may play a role in PC drug resistance. ABC transporters are a large family of transmembrane proteins with diverse physiological functio...

Full description

Bibliographic Details
Main Author:	Lo, Maisie K.Y.
Language:	English
Published:	University of British Columbia 2008
Subjects:	Pancreatic cancer Transporters Chemotherapy Resistant
Online Access:	http://hdl.handle.net/2429/1627

Similar Items

Role of transporters in pancreatic cancer drug resistance
by: Lo, Maisie K.Y.
Published: (2008)

Role of transporters in pancreatic cancer drug resistance
by: Lo, Maisie K.Y.
Published: (2008)

Role of transporters in pancreatic cancer drug resistance
by: Lo, Maisie K. Y.
Published: (2008)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
by: Lukas M. Braun, et al.
Published: (2020-05-01)

Role of the microbiome in occurrence, development and treatment of pancreatic cancer
by: Yicheng Wang, et al.
Published: (2019-12-01)

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
by: Francisco Quiñonero, et al.
Published: (2019-12-01)

Systemic drug therapy of metastatic pancreatic cancer
by: I A Pokataev, et al.
Published: (2016-03-01)

A PARADIGM SHIFT IN THE TREATMENT OF PATIENTS WITH RESECTABLE PANCREATIC CANCER
by: E. Yu. Antonova, et al.
Published: (2020-07-01)

EMT and Treatment Resistance in Pancreatic Cancer
by: Nicola Gaianigo, et al.
Published: (2017-09-01)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
by: Kamil D. Dalgatov, et al.
Published: (2021-08-01)

Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
by: Raffaele Pezzilli, et al.
Published: (2020-01-01)

ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER
by: A. V. Kozlov, et al.
Published: (2018-02-01)

Duration of therapy for locally advanced pancreatic cancer: Does it matter?
by: Richard Tuli, et al.
Published: (2020-07-01)

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
by: Mariia Kiriukova, et al.
Published: (2020-09-01)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
by: Thomas J. Ettrich, et al.
Published: (2018-12-01)

Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan
by: Junji Furuse
Published: (2019-08-01)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
by: Jinkook Kim, et al.
Published: (2021-01-01)

Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
by: Richard Fischer, et al.
Published: (2012-01-01)

Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature
by: Ester Oneda, et al.
Published: (2019-11-01)

Advanced pancreatic cancer: the standard of care and new opportunities
by: Amrallah A. Mohammad
Published: (2018-09-01)

The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study
by: Michalis V. Karamouzis, et al.
Published: (2021-06-01)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)

The Role of the Hedgehog Pathway in Chemoresistance of Gastrointestinal Cancers
by: Yabing Liang, et al.
Published: (2021-08-01)

Case Report of Exercise to Attenuate Side Effects of Treatment for Pancreatic Cancer
by: Marie McLaughlin, et al.
Published: (2019-11-01)

Pancreatic cancer- mechanisms of chemoresistance
by: Barbara Borowa-Mazgaj
Published: (2016-03-01)

Cystic gastric metastasis from pancreatic cancer
by: Naoki Umezaki, et al.
Published: (2018-04-01)

Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma
by: Ralf Jesnowski, et al.
Published: (2010-12-01)

Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer
by: Eiko Klimant, et al.
Published: (2013-01-01)

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer
by: Fan Z, et al.
Published: (2019-09-01)

Molecular Targeted Intervention for Pancreatic Cancer
by: Altaf Mohammed, et al.
Published: (2015-08-01)

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER
by: A. S. POPOVA, et al.
Published: (2017-06-01)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
by: Changhoon Yoo, et al.
Published: (2019-02-01)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
by: Heng Zhu, et al.
Published: (2020-03-01)

Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?
by: Robert Dziura, et al.
Published: (2020-06-01)

The Spectrum of Pulmonary Toxicity in Pancreatic Cancer Patients Receiving Gemcitabine Combination Chemotherapy
by: Jalal Baig, et al.
Published: (2019-07-01)

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy
by: Pei‐Wei Huang, et al.
Published: (2019-09-01)

Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone
by: Hua Chen, et al.
Published: (2018-10-01)

Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience
by: Cavanna L, et al.
Published: (2019-04-01)

Understanding the Role of the Receptor for Advanced Glycation End-Products (Rage) in Pancreatic Cancer
by: Swami, Priyanka
Published: (2019)

Circadian Genes as Therapeutic Targets in Pancreatic Cancer
by: María García-Costela, et al.
Published: (2020-09-01)